The identification of AQP4-IgG, a specific and pathogenic antibody of NMO/SD has led to a broadening of the clinical spectrum of manifestations of NMO/SD including the presence of encephalic symptoms. Lesions are often distributed on peri‑ependymal area and sometimes affected the diencephalon leading to sleep disorders. We report a case of hypersomnia with polysomnographic documentation during the first attack of NMO/SD. Brain MRI revealed bilateral hypothalamic lesions around the third ventricle, whereas optic nerves and spinal cord were intact. The record of the nocturnal video-polysomnography followed by multiple sleep latency tests (MSLT) revealed an abnormal shortened sleep period with a single sleep onset in REM allowing secondary central hypersomnia diagnosis. The recovery of hypersomnia was complete within few months without psychostimulant treatment and the diencephalic lesion disappeared. Thus, diencephalic form of NMO/SD seems to cause narcolepsy or non-narcoleptic central hypersomnia and have a good recovery.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2019.101869DOI Listing

Publication Analysis

Top Keywords

central hypersomnia
8
secondary hypersomnia
4
hypersomnia initial
4
initial manifestation
4
manifestation neuromyelitis
4
neuromyelitis optica
4
optica spectrum
4
spectrum disorders
4
disorders identification
4
identification aqp4-igg
4

Similar Publications

Study Objectives: This study examined the impact of central disorders of hypersomnolence (CDH) on family members of adult patients, the ways family members assist with managing CDH, and family members' utilization and satisfaction with information and support.

Methods: Participants were adults (N=100) with an adult family member diagnosed with idiopathic hypersomnia or narcolepsy. They completed a survey which included the Family Reported Outcome Measure (FROM-16), checklists, satisfaction ratings, and open-response questions.

View Article and Find Full Text PDF

Seasonality of excessive daytime sleepiness has been proposed, yet no research has specifically investigated its impact on daytime sleepiness and cataplexy in central disorders of hypersomnolence. This study examined seasonal variations in daytime sleepiness and cataplexy in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. Patients included in the study were on stable pharmacological treatment, and participated in sleep medicine interviews to assess diurnal sleepiness and daytime napping and completed the Epworth Sleepiness Scale to assess excessive daytime sleepiness (Epworth Sleepiness Scale ≥ 10).

View Article and Find Full Text PDF

Excessive daytime sleepiness and its predictors among type 2 diabetes mellitus patients at central ethiopia.

Sci Rep

December 2024

Department of Pediatrics and Child Health Nursing, College of Medicine and Health Sciences, Injibara University, Injibara, Ethiopia.

Excessive daytime sleepiness is a common finding among type 2 diabetes mellitus patients. However there is scarce data that shows the magnitude of excessive daytime sleepiness, & its association with type 2 diabetes mellitus. Hence, the study aimed to assess the prevalence of excessive daytime sleepiness and its associated factors among type 2 diabetes mellitus patients at Wolkite University Specialized Hospital.

View Article and Find Full Text PDF
Article Synopsis
  • Interstitial lung disease (ILD) patients often struggle with fatigue and excessive daytime sleepiness (EDS), which can significantly affect their quality of life.
  • A study conducted found that ILD patients had a higher prevalence of fatigue (40.7%) and EDS (35.2%) compared to healthy volunteers (9.8% and 14.1%, respectively).
  • Factors contributing to fatigue in ILD patients include chest pain and decreased exercise capacity, while older age and reduced physical capability are linked to EDS, indicating a need for targeted intervention and rehabilitation.
View Article and Find Full Text PDF

The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review.

Int J Mol Sci

November 2024

Department of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang 471003, China.

Article Synopsis
  • - Narcolepsy type 1 (NT1) is a rare sleep disorder characterized by excessive daytime sleepiness, cataplexy, and disruptions in REM sleep, linked to the loss of neurons that produce a wakefulness-promoting neuropeptide called orexin.
  • - The condition's onset may be influenced by factors like genetic predisposition, environmental triggers, and especially an autoimmune reaction, with a noted increase in cases following certain viral infections and vaccinations.
  • - Research highlights the role of specific T cells in attacking orexin-producing neurons, emphasizing the need for further understanding of NT1's autoimmune mechanisms to develop effective treatments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!